30 completed. 30 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 30 | Completed 30 |
| Phase 2 | 7 | Completed 7 |
Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers MMH-522 - Cough | Phase 1 | Completed | Materia Medica Holding | 16 | 2026-02-12 | 2026-09-10 |
| A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants GSK5464714- Camlipixant - Cough | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 14 | 2024-07-09 | 2025-02-07 |
| A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age Camlipixant - Cough | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 32 | 2024-02-02 | 2026-01-07 |
| Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant Camlipixant, Dabigatran etexilate, Gemfibrozil - Cough, Healthy | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 45 | 2023-07-26 | 2025-03-26 |
| Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant Camlipixant, Rabeprazole, Rifampin - Cough, Healthy | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 42 | 2023-06-21 | 2024-12-04 |
| Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation BLU-5937 IR, BLU-5937 ER - Cough, Healthy | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 30 | 2022-10-07 | 2025-05-18 |
| Alleviation of Common Cold Symptoms Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet - Common Cold, Pharyngitis | Phase 1 | Completed | Applied Biological Laboratories Inc | 157 | 2022-05-25 | 2024-01-16 |
| A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration HRS-2261 tablet、placebo - Chronic Cough | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 92 | 2022-03-28 | 2023-04-05 |
| Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI) - Refractory Chronic Cough | Phase 1 | Completed | Nocion Therapeutics | 24 | 2022-02-07 | 2023-03-30 |
| Cough Desensitization Therapy: Pilot 2 Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline - Cough | Phase 1 | Completed | University of Montana | 22 | 2021-05-01 | 2022-11-03 |
| Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants BAY1817080, Moxifloxacin, Placebo - Cough, Endometriosis | Phase 1 | Completed | Bayer | 42 | 2020-06-18 | 2022-01-24 |
| Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants Rosuvastatin, Rosuvastatin + BAY1817080 - Drug Interactions | Phase 1 | Completed | Bayer | 14 | 2020-03-02 | 2021-03-11 |
| A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein BAY1817080 - Formulation A, BAY1817080 - Formulation B, [13C715N]-BAY 181708 stable isotope label (SIL) - Biological Availability | Phase 1 | Completed | Bayer | 30 | 2018-12-13 | 2019-08-19 |
| BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect BLU-5937, Placebo - Cough | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 90 | 2018-07-09 | 2018-11-09 |
| Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients BAY1902607, Matching placebo, Midazolam - Cough | Phase 1 / Phase 2 | Completed | Bayer | 59 | 2018-05-29 | 2021-02-10 |
| Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients BAY1817080, Matching Placebo - Cough | Phase 1 / Phase 2 | Completed | Bayer | 87 | 2017-12-07 | 2023-01-26 |
| Cough According to Stimulus Type in PD Capsaicin vapor, fog, Videofluoroscopic swallow evaluation - Parkinson's Disease | Phase 1 | Completed | University of Florida | 158 | 2015-04-01 | 2019-02-15 |
| Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease Capsaicin, Voluntary cough test - Cough, Parkinson's Disease | Phase 1 / Phase 2 | Completed | University of Florida | 44 | 2014-10-01 | 2017-03-24 |
| Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study Codeine Phosphate/Guaifenesin ER Tablet, Codeine Phosphate/Guaifenesin IR Tablet - Cough | Phase 1 | Completed | Nexgen Pharma, Inc | 38 | 2014-10-01 | 2017-03-29 |
| Single Dose Trial of Extended Release Combination Tablet Codeine and Guaifenesin IR Tablet under Fasted conditions, ER Tablet under Fed Conditions, ER Tablet under Fasted Conditions - Cough | Phase 1 | Completed | Nexgen Pharma, Inc | 26 | 2014-06-01 | 2015-04-15 |
Showing 20 of 30. Sign in to see all of them.
Chronic Cough (7) · Parkinson Disease (3) · Deglutition Disorders (2) · Endometriosis (2) · Pulmonary Disease, Chronic Obstructive (2) · Asthma (1) · Common Cold (1) · Fever (1) · Headache (1) · Inflammation (1) · Ischemic Stroke (1) · Pain (1) · Pharyngitis (1) · Pneumonia, Aspiration (1)
Pathological Conditions, Signs and Symptoms (30) · Respiration Disorders (30) · Respiratory Tract Diseases (30) · Signs and Symptoms (30) · Signs and Symptoms, Respiratory (30) · Nervous System Diseases (5) · Brain Diseases (4) · Central Nervous System Diseases (4) · Lung Diseases (4) · Pathologic Processes (4) · Basal Ganglia Diseases (3) · Infections (3) · Lung Diseases, Obstructive (3) · Movement Disorders (3)
Capsaicin (3) · Codeine (2) · Sodium Chloride (2) · Accidental Falls (1) · Aspirin (1) · BLU-5937 (1) · Biological Products (1) · DNK 333 (1) · Dabigatran (1) · Dextromethorphan (1) · Gemfibrozil (1) · Guaifenesin (1) · Inhalation (1) · Lidocaine (1) · Midazolam (1)
Bellus Health Inc. - a GSK company (6) · Bayer (5) · University of Florida (5) · GlaxoSmithKline (2) · Nexgen Pharma, Inc (2) · Novartis (2) · Applied Biological Laboratories Inc (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Materia Medica Holding (1) · Nocion Therapeutics (1) · Penn State University (1) · Pfizer (1) · University of Montana (1) · University of South Florida (1)
United States (14) · United Kingdom (6) · Canada (4) · Netherlands (3) · Jordan (2) · China (1) · Germany (1) · Russia (1)
Karen W Hegland, PHD (2) · Alexandra E. Brandimore, M.A. (1) · Alexandra E. Brandimore, M.A. CCC/SLP (1) · Christine M Sapienza, Ph.D. (1) · Christopher Silber, MD (1) · Ian M Paul, MD, MSc (1) · Karen W. Hegland, Ph.D. (1) · Laurie Slovarp, PhD (1) · Nazlie Latefi, PhD (1) · Rana T Bustami, PhD (1)
PMID 12493340, PMID 18056558, PMID 19029430, PMID 27130637, PMID 33986030, PMID 35624408, PMID 36469250, PMID 37041539, PMID 37118696, PMID 38044419, PMID 38198010, PMID 39602479
2018 (2), 2017 (1), R21DC014567 (1)